巨细胞动脉炎：2018年综述
Giant Cell Arteritis: 2018 Review.
作者信息
Winkler Anne, True David
机构信息
Anne Winkler, MD, PhD, MACP, FACR, MSMA member since 2003, on the Editorial Board for Rheumatology for Missouri Medicine. She is on the clinical faculty of Missouri State University in Southwest Missouri and has been principal investigator in multiple clinical trials.
David True, DO, FACR, practices rheumatology in Southwest Missouri and has been principal investigator in multiple clinical trials.
出版信息
Mo Med. 2018 Sep-Oct;115(5):468-470.
Abstract
Giant cell arteritis is the most common large vessel vasculitis. Classic symptoms include headaches, scalp tenderness, visual loss and muscle stiffness and pain. First line treatment is with high dose steroids but methotrexate may be of some help in decreasing steroid use. Tocilizumab has been shown to significantly decrease relapse rate and lower steroid cumulative dose.
摘要
巨细胞动脉炎是最常见的大血管血管炎。典型症状包括头痛、头皮压痛、视力丧失以及肌肉僵硬和疼痛。一线治疗是使用高剂量类固醇，但甲氨蝶呤在减少类固醇使用方面可能会有所帮助。已证明托珠单抗可显著降低复发率并降低类固醇累积剂量。
相似文献
1
Giant Cell Arteritis: 2018 Review.
Mo Med. 2018 Sep-Oct;115(5):468-470.
2
Efficacy of tocilizumab in refractory giant cell arteritis.
Joint Bone Spine. 2012 May;79(3):317-8. doi: 10.1016/j.jbspin.2011.11.008. Epub 2012 Jan 27.
3
Tocilizumab in the treatment of giant cell arteritis.
Immunotherapy. 2018 Mar 1;10(6):465-472. doi: 10.2217/imt-2017-0182. Epub 2018 Mar 5.
4
Is visual loss due to giant cell arteritis reversible?
Yonsei Med J. 2003 Feb;44(1):155-8. doi: 10.3349/ymj.2003.44.1.155.
5
Immunosuppressive treatment for giant cell arteritis: where do we stand?
Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-5-6. Epub 2015 May 25.
6
Polymyalgia Rheumatica and Giant Cell Arteritis.
JAMA. 2020 Sep 8;324(10):993-994. doi: 10.1001/jama.2020.10155.
7
Tocilizumab for giant cell arteritis: an amazing result.
Rheumatol Int. 2013 Nov;33(11):2961-2. doi: 10.1007/s00296-012-2516-z. Epub 2012 Sep 11.
8
[Large-vessel vasculitis-giant cell and Takayasu arteritis].
Internist (Berl). 2019 Oct;60(10):1059-1073. doi: 10.1007/s00108-019-00666-2.
9
Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
J Rheumatol. 2016 Aug;43(8):1547-52. doi: 10.3899/jrheum.151252. Epub 2016 May 15.
10
A case of scalp necrosis.
Clin Exp Dermatol. 2019 Jan;44(1):106-109. doi: 10.1111/ced.13656. Epub 2018 Jun 27.
引用本文的文献
1
Cardiology-Rheumatology Intersections in Aortitis and Aortic Aneurysms: Focus on Early Recognition and Management.
JACC Case Rep. 2024 Dec 4;29(23):102818. doi: 10.1016/j.jaccas.2024.102818.
2
Association of clinical, imaging and laboratory parameters with adverse effects of glucocorticoid therapy in patients with giant cell arteritis.
Front Med (Lausanne). 2024 May 22;11:1382946. doi: 10.3389/fmed.2024.1382946. eCollection 2024.
3
A Case of Large Vessel Giant Cell Arteritis Presenting With Cough and Diagnosed Using an FDG-PET Scan.
Cureus. 2024 May 5;16(5):e59686. doi: 10.7759/cureus.59686. eCollection 2024 May.
4
Oxidative stress in the eye and its role in the pathophysiology of ocular diseases.
Redox Biol. 2023 Dec;68:102967. doi: 10.1016/j.redox.2023.102967. Epub 2023 Nov 18.
5
Giant cell arteritis with severe intracranial involvement diagnosed and treated early.
Surg Neurol Int. 2023 Sep 15;14:332. doi: 10.25259/SNI_529_2023. eCollection 2023.
6
Oxidative Stress: A Suitable Therapeutic Target for Optic Nerve Diseases?
Antioxidants (Basel). 2023 Jul 20;12(7):1465. doi: 10.3390/antiox12071465.
7
From Temporal Cell Arteritis to Giant Cell Aortitis Presenting as a Constitutional Syndrome: A Case Report.
Cureus. 2023 Jan 25;15(1):e34181. doi: 10.7759/cureus.34181. eCollection 2023 Jan.
8
A Case Report of Immune Checkpoint Inhibitor-Induced Aortitis Treated with Tocilizumab.
Case Reports Immunol. 2022 Oct 12;2022:7971169. doi: 10.1155/2022/7971169. eCollection 2022.
9
Evidence-based Role of Aspirin in Giant Cell Arteritis: A Literature Review.
J Community Hosp Intern Med Perspect. 2022 Sep 9;12(5):11-16. doi: 10.55729/2000-9666.1072. eCollection 2022.
10
Giant Cell Arteritis: A Case-Based Narrative Review of the Literature.
Curr Pain Headache Rep. 2022 Oct;26(10):725-740. doi: 10.1007/s11916-022-01075-1. Epub 2022 Sep 3.
本文引用的文献
1
Trial of Tocilizumab in Giant-Cell Arteritis.
N Engl J Med. 2017 Jul 27;377(4):317-328. doi: 10.1056/NEJMoa1613849.
2
Giant cell arteritis.
Best Pract Res Clin Rheumatol. 2016 Feb;30(1):169-88. doi: 10.1016/j.berh.2016.05.001. Epub 2016 Jun 20.
3
Ustekinumab for the treatment of refractory giant cell arteritis.
Ann Rheum Dis. 2016 Aug;75(8):1578-9. doi: 10.1136/annrheumdis-2016-209351. Epub 2016 May 3.
4
2015 ACR/ARHP Annual Meeting Abstract Supplement.
Arthritis Rheumatol. 2015 Oct;67 Suppl 10:1-4046. doi: 10.1002/art.39448.
5
New insights into the pathogenesis of giant cell arteritis and hopes for the clinic.
Expert Rev Clin Immunol. 2016;12(1):57-66. doi: 10.1586/1744666X.2016.1089173. Epub 2015 Sep 14.
6
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.
Am J Hum Genet. 2015 Apr 2;96(4):565-80. doi: 10.1016/j.ajhg.2015.02.009. Epub 2015 Mar 26.
7
Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.
Ann Rheum Dis. 2014 Dec;73(12):2074-81. doi: 10.1136/annrheumdis-2013-203586. Epub 2013 Jul 29.
8
Genetic component of giant cell arteritis.
Rheumatology (Oxford). 2014 Jan;53(1):6-18. doi: 10.1093/rheumatology/ket231. Epub 2013 Jul 10.
9
Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment.
Autoimmun Rev. 2012 May;11(6-7):A544-54. doi: 10.1016/j.autrev.2012.01.003. Epub 2012 Jan 21.
10
Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: Clinical features and epidemiological data.
Clin Exp Rheumatol. 2009 Sep-Oct;27(5):830-3.
Zotero 插件